Angelo Avogaro to Benzhydryl Compounds
This is a "connection" page, showing publications Angelo Avogaro has written about Benzhydryl Compounds.
Connection Strength
2.228
-
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):763-772.
Score: 0.535
-
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017 04 04; 16(1):42.
Score: 0.532
-
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr; 18(5):517-527.
Score: 0.530
-
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 02; 21(2):252-260.
Score: 0.147
-
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
Score: 0.142
-
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
Score: 0.136
-
Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15; 241:450-456.
Score: 0.133
-
Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018 10 01; 103(10):3773-3782.
Score: 0.037
-
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
Score: 0.035